Compare Torrent Pharma with ALEMBIC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ALEMBIC - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ALEMBIC TORRENT PHARMA/
ALEMBIC
 
P/E (TTM) x 37.0 77.6 47.7% View Chart
P/BV x 9.4 6.7 140.1% View Chart
Dividend Yield % 0.6 0.2 426.1%  

Financials

 TORRENT PHARMA   ALEMBIC
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
ALEMBIC
Mar-18
TORRENT PHARMA/
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs1,96472 2,727.8%   
Low Rs1,24534 3,672.6%   
Sales per share (Unadj.) Rs453.44.7 9,646.0%  
Earnings per share (Unadj.) Rs25.86.1 422.4%  
Cash flow per share (Unadj.) Rs62.36.2 997.3%  
Dividends per share (Unadj.) Rs17.000.20 8,500.0%  
Dividend yield (eoy) %1.10.4 280.5%  
Book value per share (Unadj.) Rs279.240.7 686.6%  
Shares outstanding (eoy) m169.22267.03 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.511.3 31.4%   
Avg P/E ratio x62.28.7 717.3%  
P/CF ratio (eoy) x25.88.5 303.8%  
Price / Book Value ratio x5.71.3 441.3%  
Dividend payout %65.93.3 2,012.2%   
Avg Mkt Cap Rs m271,51314,139 1,920.3%   
No. of employees `00013.6NA-   
Total wages/salary Rs m14,038207 6,768.5%   
Avg. sales/employee Rs Th5,642.6NM-  
Avg. wages/employee Rs Th1,032.4NM-  
Avg. net profit/employee Rs Th320.9NM-  
INCOME DATA
Net Sales Rs m76,7281,255 6,112.8%  
Other income Rs m571370 154.1%   
Total revenues Rs m77,2991,625 4,755.7%   
Gross profit Rs m19,831111 17,849.3%  
Depreciation Rs m6,17738 16,341.0%   
Interest Rs m5,0382 296,323.5%   
Profit before tax Rs m9,187442 2,079.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,25424 5,233.8%   
Profit after tax Rs m4,3631,630 267.7%  
Gross profit margin %25.88.9 292.0%  
Effective tax rate %13.65.4 251.7%   
Net profit margin %5.7129.8 4.4%  
BALANCE SHEET DATA
Current assets Rs m50,3751,867 2,698.1%   
Current liabilities Rs m51,653591 8,737.0%   
Net working cap to sales %-1.7101.6 -1.6%  
Current ratio x1.03.2 30.9%  
Inventory Days Days9294 97.7%  
Debtors Days Days6874 92.9%  
Net fixed assets Rs m83,6481,791 4,670.7%   
Share capital Rs m846534 158.4%   
"Free" reserves Rs m46,39710,324 449.4%   
Net worth Rs m47,24410,858 435.1%   
Long term debt Rs m39,12941 94,973.8%   
Total assets Rs m141,20911,591 1,218.3%  
Interest coverage x2.8260.9 1.1%   
Debt to equity ratio x0.80 21,827.3%  
Sales to assets ratio x0.50.1 501.7%   
Return on assets %6.714.1 47.3%  
Return on equity %9.215.0 61.5%  
Return on capital %12.315.2 81.2%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m22,10319 113,930.9%   
Fx outflow Rs m5,522264 2,092.9%   
Net fx Rs m16,581-244 -6,783.9%   
CASH FLOW
From Operations Rs m17,981236 7,625.4%  
From Investments Rs m-2,413-224 1,077.1%  
From Financial Activity Rs m-13,145-27 49,415.4%  
Net Cashflow Rs m2,380-15 -16,082.4%  

Share Holding

Indian Promoters % 71.5 64.0 111.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.2 3,510.0%  
FIIs % 12.6 9.7 129.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 26.1 33.7%  
Shareholders   26,511 54,701 48.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT PHARMOVA   SUN PHARMA  PIRAMAL ENTERPRISES  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS